✦ LIBER ✦

Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan

✍ Scribed by Yeh, Chun-Nan; Chen, Yen-Yang; Tseng, Jeng-Hwei; Chen, Jen-Shi; Chen, Tsung-Wen; Tsai, Chun-Yi; Cheng, Chi-Tung; Jan, Yi-Yin; Chen, Miin-Fu

Book ID: 122333355
Publisher: Elsevier
Year: 2011
Tongue: English
Weight: 602 KB
Volume: 4
Category: Article
ISSN: 1936-5233
DOI: 10.1593/tlo.11253

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A long-term follow-up of the imatinib me

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

✍ Jiang Zhu; Yu Yang; Lin Zhou; Ming Jiang; Mei Hou 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 641 KB

4526 POSTER Safety profile of single-age

4526 POSTER Safety profile of single-agent sunitinib malate from the French Temporary Authorization for Use program (Cohort ATU) in metastatic renal cell carcinoma (MRCC) after failure of treatment with cytokines and gastrointestinal stromal tumor (GIST) patients after failure of imatinib mesylate treatment

✍ Oudard, S.; Negrier, S.; Ferrero, J.M.; Gravis, G.; Blay, J.Y.; Le Cesne, A.; Kr 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Tumeur stromales non résécables traitées

Tumeur stromales non résécables traitées par Imatinib : doit-on faire l’ablation des lésions résiduelles ?: C. Scaife, K. Hunt, S. Patel, R. Benjamin, M. Burgess, L. Chen, J. Trent, K. Raymond, J. Cormier, P. Pister, R. Pollock, B. Feig Is there a role for surgery in patients with “unresectable” c KIT + gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003;186:665-669

✍ B. Dousset; Ph. de Mestier; C. Vons 📂 Article 📅 2004 🏛 Masson Editeur 🌐 French ⚖ 57 KB